Comparative Pharmacology
Head-to-head clinical analysis: QBREXZA versus TOLTERODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QBREXZA versus TOLTERODINE.
QBREXZA vs TOLTERODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective D1 and D5 dopamine receptor antagonist; reduces dopamine-mediated vasodilation in choroidal blood vessels, decreasing choroidal thickness and neovascularization.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), with selectivity for the M3 receptor subtype involved in detrusor muscle contraction, reducing bladder smooth muscle contractility and increasing bladder capacity.
1 capsule (40 mg) orally twice daily with or without food.
2 mg PO twice daily; may reduce to 1 mg twice daily if tolerated.
None Documented
None Documented
Terminal elimination half-life is approximately 150 hours (range 120-200 hours), supporting once-daily dosing without significant accumulation.
Clinical Note
moderateTolterodine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Tolterodine."
Clinical Note
moderateTolterodine + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Tolterodine."
Clinical Note
moderateTolterodine + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Tolterodine."
Clinical Note
moderateTolterodine + Clotrimazole
Terminal elimination half-life is 2-4 hours in extensive CYP2D6 metabolizers; increased to 4-10 hours in poor metabolizers or with CYP3A4 inhibitors.
Renal: approximately 30% as unchanged drug; fecal: approximately 60% as metabolites and parent compound; biliary excretion contributes to fecal elimination.
Primarily hepatic metabolism via CYP2D6 and CYP3A4; renal excretion accounts for <5% of unchanged drug; ~80% excreted in urine as metabolites, ~20% in feces.
Category C
Category A/B
Anticholinergic
Anticholinergic
"The metabolism of Clotrimazole can be decreased when combined with Tolterodine."